Michael D. Goldberg Insider Information

Michael Goldberg has served as a member and chairman of our board of directors since November 2011. From January 2005 to May 2011, Mr. Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular diagnostics, personalized medicine, and wireless healthcare. From October 2000 to December 2004, Mr. Goldberg operated a management and financial consultancy business. In 1995, Mr. Goldberg founded OnCare, Inc., an oncology disease management company, and served as chairman until August 2001 and as chief executive officer until March 1999. In 1987, Mr. Goldberg founded Axion, Inc., a cancer treatment services company, and served as chief executive officer until its sale to Bristol-Myers Squibb in 1995. Prior to Axion, Mr. Goldberg was a partner at the venture capital firm, Sevin Rosen Management Company, from 1985 to 1987, where he established the firm’s life science practice, and was director of corporate development at Cetus Corporation from 1981 to 1985. Mr. Goldberg has served as a member of the board of directors of numerous companies in the biotech and health sciences industry, and currently serves as executive chairman of DNAnexus, Inc. Mr. Goldberg has served on boards and advisory boards of a number of industry, academic, and public policy institutions in biotechnology and finance, including the board of the Independent Citizens Oversight Committee, which is the governing board for the California Institute for Regenerative Medicine, the board of the Western Association of Venture Capitalists, the advisory boards of the Harvard Center for Genetics and Genomics, the Berkeley Center for Law and Technology, and the UCSF Center for Translational and Policy Research on Personalized Medicine. Mr. Goldberg holds a BA from Brandeis University and an MBA from the Stanford Graduate School of Business.